Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Dec;98(12):1636-41.
doi: 10.1136/bjophthalmol-2014-305252. Epub 2014 Jul 7.

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

Robert L Avery  1 , Alessandro A Castellarin  1 , Nathan C Steinle  1 , Dilsher S Dhoot  1 , Dante Joseph Pieramici  1 , Robert See  1 , Stephen Couvillion  1 , Ma'an A Nasir  1 , Melvin D Rabena  1 , Kha Le  2 , Mauricio Maia  2 , Jennifer E Visich  2
Affiliations
Free PMC article
Comparative Study

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

Robert L Avery et al. Br J Ophthalmol. 2014 Dec.
Free PMC article

Abstract

Background: Data comparing systemic exposure and systemic vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following intravitreal injection are lacking.

Methods: Fifty-six patients with wet age-related macular degeneration received intravitreal ranibizumab (0.5 mg), bevacizumab (1.25 mg), or aflibercept (2.0 mg). Serum pharmacokinetics and plasma free VEGF were evaluated after the first and third injections.

Results: Following the first dose, systemic exposure to aflibercept was 5-, 37-, and 9-fold higher than ranibizumab, whereas, bevacizumab was 9-, 310-, and 35-fold higher than ranibizumab, based on geometric mean ratio of peak and trough concentrations and area under the curve, respectively. The third dose showed accumulation of bevacizumab and aflibercept but not ranibizumab. Aflibercept substantially suppressed plasma free VEGF, with mean levels below lower limit of quantitation (10 pg/mL) as early as 3 h postdose until ≥7 days postdose. Mean free (unbound) VEGF levels with ranibizumab were largely unchanged, with mean trough level of 14.4 pg/mL compared with baseline of 17 pg/mL.

Conclusions: There are notable differences in systemic pharmacokinetics and pharmacodynamics among anti-VEGF treatments after intravitreal administration. All three agents rapidly moved into the bloodstream, but ranibizumab very quickly cleared, whereas bevacizumab and aflibercept demonstrated greater systemic exposure and produced a marked reduction in plasma free VEGF.

Trial registration number: NCT02118831.

Keywords: Retina.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serum concentration–time curves for ranibizumab, bevacizumab, or aflibercept following intravitreal injection in patients with age-related macular degeneration.
Figure 2
Figure 2
Mean (95% CI) plasma free VEGF concentration following intravitreal injection of ranibizumab, bevacizumab, or aflibercept in patients with age-related macular degeneration. VEGF, vascular endothelial growth factor.
Figure 3
Figure 3
Individual observed plasma free VEGF concentrations following intravitreal injection of ranibizumab, bevacizumab, or aflibercept. ITV, intravitreal; VEGF, vascular endothelial growth factor.
See this image and copyright information in PMC

References

    1. Rothen M, Jablon E, Monares G, et al. Anti-macular degeneration agents. Ophthalmol Clin North Am 2005;18:561–7. - PubMed
    1. Avastin (bevacizumab) solution for intravenous infusion prescribing information. http://www.gene.com/download/pdf/avastin_prescribing.pdf (accessed 11 Mar 2014).
    1. Lucentis (ranibizumab injection) intravitreal injection prescribing information. http://www.gene.com/download/pdf/lucentis_prescribing.pdf (accessed 11 Mar 2014).
    1. Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 2013;54:1616–24. - PubMed
    1. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859–70. - PubMed

Publication types

MeSH terms

Associated data